Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
162,163 Retatrutide (LY-3437943), a novel triple agonist developed by Eli Lilly that targets GLP-1R, GIPR and GCGR, has shown potential in preliminary clinical data for providing excellent blood sugar control and significant weight reduction
Phase 2 trial results demonstrated up to 19% body weight reduction after 46 weeks at the highest dose (4.8 mg)
Reverses corticosteroid-induced tissue damage
Join us in exploring the fascinating world of peptides and their potential applications in healthcare and medicine
The production of melanin is influenced by genetic factors
US$ 25.28
US$ 23.33
US$ 23.32
US$ 24.29
US$ 25.90
US$ 29.06
